Lemetre (40) and Berg (41), respectively, used the TCGA database and their own endometrial cancer samples to analyze and found that MSH6 was an independent prognostic marker, and patients with low expression of MSH6 had better survival outcomes. Here, MSH6 is linked to endometrial cancer.